TG Therapeutics Q3 BRIUMVI revenue $83.3M, raises FY2024 guidance to $300-$305M

TG THERAPEUTICS, INC.

2024-Q3 EPS reported $0.00 revenue$220,819,000

BRIUMVI Q3 U.S. net sales $83.3M, up 15% QoQ and 230% YoY; full-year target raised to $300-$305M.
Net income $3.9M in Q3 vs $113.9M a year ago (prior period included $140M upfront payment); cash $341M.
Phase 1 trial of subcutaneous ublituximab initiated; FDA cleared IND for azer-cel in progressive MS.
Secured FUJIFILM Diosynth as secondary U.S. manufacturer of BRIUMVI.
Five-year ECTRIMS data: 92% of patients free from disability progression; annualized relapse rate 0.02.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.